(Q54141536)

25 May 2018

title

Lisinopril in hypertensive patients with and without renal failure. (English)

1 reference

25 May 2018

author name string

B A van Schaik

series ordinal

1

1 reference

25 May 2018

G G Geyskes

series ordinal

2

1 reference

25 May 2018

P Boer

series ordinal

3

1 reference

25 May 2018

publication date

1 January 1987

1 reference

25 May 2018

European Journal of Clinical Pharmacology

published in

1 reference

25 May 2018

volume

32

1 reference

25 May 2018

issue

1

1 reference

25 May 2018

page(s)

11-16

1 reference

25 May 2018

Effects of repeated doses of enalapril on renal function in man.

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00609951

Blood and extracellular fluid volume in patients with Bartter's syndrome

21 January 2018

1 reference

12 December 2020

Comparative Studies: Enalapril Versus Hydrochlorothiazide as First-Step Therapy for the Treatment of Primary Hypertension

1 reference

12 December 2020

Effects of chronic administration of enalapril and propranolol on the large arteries in essential hypertension.

1 reference

12 December 2020

Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

1 reference

12 December 2020

Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension

1 reference

12 December 2020

Increased Glomerular Filtration Rate after Converting-Enzyme Inhibition in Essential Hypertension

1 reference

12 December 2020

Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure

1 reference

12 December 2020

Optimized assay for serum angiotensin-converting enzyme activity

1 reference

12 December 2020

Enalapril maleate and a lysine analogue (MK-521): disposition in man

1 reference

12 December 2020

ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421"

1 reference

12 December 2020

Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor

1 reference

12 December 2020

Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man.

1 reference

12 December 2020

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects

1 reference

12 December 2020

Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system

1 reference

12 December 2020

Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521

1 reference

12 December 2020

The effects of enalapril on blood pressure and the kidney in normotensive subjects under altered sodium balance

1 reference

12 December 2020

Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor

1 reference

12 December 2020

Pharmacokinetics of enalapril in normal subjects and patients with renal impairment

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00609951

1 reference

25 May 2018

1 reference

25 May 2018